首页 > 市场调查报告书 > 製药

癌症

2030 年亚太地区乳癌治疗市场预测 - 区域分析 - 按药物治疗、乳癌类型和配销通路

市场调查报告书

商品编码

1481919

2030 年亚太地区乳癌治疗市场预测 - 区域分析 - 按药物治疗、乳癌类型和配销通路

Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 106 Pages | 订单完成后即时交付

价格

简介目录图表

2022年亚太地区乳癌治疗市值为698,637万美元，预计2030年将达1581983万美元；预计2022年至2030年复合年增长率为10.8%。

多项诊断和筛检计画的推出推动了亚太地区乳癌治疗市场的发展

个人化医疗、免疫疗法、联合疗法、药物输送系统、液体活检、人工智慧和以患者为中心的方法的进步预计将塑造乳癌治疗的未来。这些趋势旨在改善治疗结果、减少副作用并提高乳癌患者的整体生活品质。

早期疾病检测在改善患者预后和存活率方面发挥重要作用。各种组织和医疗保健提供者正在实施筛检计划，以便在乳癌更容易治疗的初始阶段检测出乳癌。世界卫生组织于2013 年2 月发布了新的全球乳癌倡议框架，作为一项计划，旨在实现到2040 年使250 万人免遭乳癌侵害的目标。世界癌症日之前公布该运动敦促各国遵循健康促进的三大支柱，以实现乳癌的早期发现、及时诊断和彻底管理。这些计划通常包括乳房X光检查、临床乳房检查和自我乳房检查，以识别乳癌的任何异常或征兆。实施这些计划提高了人们对乳癌病例的认识和早期发现，从而对有效治疗方法提出了更高的需求。

此外，全球范围内见证了诊断技术的许多进步。美国国家医学图书馆指出，早期检测和精确诊断对于改善预后至关重要。乳癌评估经常使用放射影像方式，例如数位乳房 X 光摄影 (DM)、数位乳房断层合成 (DBT)、磁振造影 (MRI)、超音波 (US) 和核子医学程序。组织病理学 (HP) 是确定癌症是否存在的黄金标准。此外，使用人工智慧（AI）技术定量描述医学影像对于改善乳癌分割、诊断和预后具有巨大潜力。这些技术可帮助医疗保健提供者确定肿瘤的范围和特征，使他们能够制定个人化的治疗计划。因此，诊断和筛检计画的启动，加上诊断技术的进步，有助于亚太地区乳癌治疗市场的成长。

亚太地区乳癌治疗市场概况

亚太地区的乳癌治疗市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。市场成长的原因包括女性乳癌负担的增加以及个人化医疗、免疫疗法、联合疗法和药物传递系统的进步。

由于乳癌盛行率上升、人口老化加剧、生活方式改变等，预计未来几年中国乳癌治疗市场将大幅成长。根据美国疾病管制与预防中心(CDC) 2023 年4 月14 日发布的统计数据，2020 年中国的新诊断病例占全球新诊断病例的24%，占全球癌症相关死亡人数的30%。十年中，乳癌的年龄标准化发生率从17.07从1990 年的每10 万人增加到2019 年的每10 万人35.61 人。重要的作用。

此外，十分之一的日本女性会在某个时候罹患乳癌。 10 月的粉红丝带运动和其他措施提高了日本民众对这种疾病的认识，包括自我检查和其他早期检测方法的重要性，这些方法一旦使用，可以将存活率提高到 90% 以上。然而，典型风险变数的识别是滞后的。因此，由于人口老化、治疗选择、政府措施和政策、高医疗保健支出、意识提高和技术进步，日本乳癌治疗市场预计将显着增长。

亚太地区乳癌治疗市场收入及 2030 年预测（百万美元）

亚太地区乳癌治疗市场区隔

亚太地区乳癌治疗市场根据药物治疗、乳癌类型和配销通路进行细分。

根据药物治疗，亚太地区乳癌治疗市场分为标靶药物治疗、荷尔蒙药物治疗、化疗和免疫治疗/生物治疗。标靶药物治疗细分市场在2022年占据了更大的份额。 emtansine、palbociclib、trastuzumab和其他标靶药物治疗。此外，荷尔蒙药物治疗部分分为选择性雌激素受体调节剂、芳香酶抑制剂和选择性雌激素受体下调剂。

就乳癌类型而言，亚太地区乳癌治疗市场分为荷尔蒙受体乳癌、HER2+乳癌和三阴性乳癌。 2022 年，荷尔蒙受体细分市场将占据更大份额。

依配销通路，亚太乳癌治疗市场分为医院药局、药局和零售药局、网路药局。 2022年，医院药局部门将占据更大的份额。

依国家/地区划分，亚太地区乳癌治疗市场分为澳洲、中国、印度、日本、韩国和亚太地区其他地区。 2022年，中国将主导亚太乳癌治疗市场。

礼来公司、卫材有限公司、诺华公司、阿斯特捷利康公司、辉瑞公司、吉利德科学公司、默克公司、梯瓦製药工业有限公司、安进公司和安进公司是在亚太地区经营乳房业务的一些领先公司癌症治疗市场。

Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.

Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.

In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Asia Pacific breast cancer therapeutics market growth.

Asia Pacific Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including growing burden of breast cancers among women coupled with advancements in personalized medicine, immunotherapy, combination therapies, and drug delivery systems.

The breast cancer therapeutics market in China is projected to witness substantial growth in the coming years, owing to the rising prevalence of breast cancer, increasing aging population, lifestyle changes, and others. China accounted for 24% of cases with new diagnoses and 30% of cancer-related fatalities globally in 2020, as per CDC statistics published on April 14, 2023. Over the last three decades, the age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019. Advancements in treatment options have played a crucial role in driving the demand for breast cancer therapeutics in China.

Also, out of 1 in 10 women in Japan will acquire breast cancer at some point. The pink ribbon campaign in October and other initiatives have raised awareness of the disease among Japanese people, including the importance of self-checks and other early detection methods that, when used, increase the survival rate to over 90%. The identification of typical risk variables, however, lags. Thus, the breast cancer therapeutics market in Japan is expected to grow significantly due to an aging population, treatment options, government initiatives and policies, high healthcare expenditure, rising awareness, and technological advancements.

Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Breast Cancer Therapeutics Market Segmentation

The Asia Pacific breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc are some of the leading companies operating in the Asia Pacific breast cancer therapeutics market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics

4.1 Key Market Drivers
- 4.1.1 Growing Burden of Breast Cancer
- 4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
- 4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
- 4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - Asia Pacific Market Analysis

5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
- 6.3.1 Overview
- 6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
- 6.4.1 Overview
- 6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
- 6.5.1 Overview
- 6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
- 6.6.1 Overview
- 6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
- 7.3.1 Overview
- 7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
- 7.4.1 Overview
- 7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
- 7.5.1 Overview
- 7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Breast Cancer Therapeutics Market -Country Analysis

9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
- 9.1.1 Overview
- 9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
- 9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
  - 9.1.3.1 China
    - 9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.2 Japan
    - 9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.3 India
    - 9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.4 Australia
    - 9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.5 South Korea
    - 9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.6 Rest of Asia Pacific
    - 9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Eli Lilly and Co
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eisai Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Novartis AG
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 AstraZeneca Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Pfizer Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Gilead Sciences Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Merck & Co Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Amgen Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation
Table 2. Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. China Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. China Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. China Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. China Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. China Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Japan Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. India Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. India Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. India Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. India Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. India Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. South Korea Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

Figure 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market